219 related articles for article (PubMed ID: 17385195)
1. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Monami M; Balzi D; Lamanna C; Barchielli A; Masotti G; Buiatti E; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
[TBL] [Abstract][Full Text] [Related]
2. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Khalangot M; Tronko M; Kravchenko V; Kovtun V
Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
[TBL] [Abstract][Full Text] [Related]
3. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
4. Sulphonylureas and cancer: a case-control study.
Monami M; Lamanna C; Balzi D; Marchionni N; Mannucci E
Acta Diabetol; 2009 Dec; 46(4):279-84. PubMed ID: 19082520
[TBL] [Abstract][Full Text] [Related]
5. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides.
Mannucci E; Monami M; Masotti G; Marchionni N
Diabetes Metab Res Rev; 2004; 20(1):44-7. PubMed ID: 14737744
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
7. 'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas.
Bilinska M; Potocka J; Korzeniowska-Kubacka I; Piotrowicz R
Coron Artery Dis; 2007 Sep; 18(6):455-62. PubMed ID: 17700217
[TBL] [Abstract][Full Text] [Related]
8. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
Jennings PE; Belch JJ
Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
[TBL] [Abstract][Full Text] [Related]
9. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].
Rupprecht E; König E; Limmer J
Pol Tyg Lek; 1993 Apr; 48 Suppl 1():31-2. PubMed ID: 8516203
[No Abstract] [Full Text] [Related]
11. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
Juurlink DN; Gomes T; Shah BR; Mamdani MM
Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
[TBL] [Abstract][Full Text] [Related]
12. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
Kardas P
Diabetes Obes Metab; 2005 Nov; 7(6):722-8. PubMed ID: 16219016
[TBL] [Abstract][Full Text] [Related]
13. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K
J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
[TBL] [Abstract][Full Text] [Related]
14. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H
Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999
[TBL] [Abstract][Full Text] [Related]
15. Urinary PC-1 and N-acetyl-beta-D-glucosaminidase activity in patients with type 2 diabetes treated with metformin, gliclazide or glibenclamide.
Stefanović V; Antić S; Mitić-Zlatković M; Stojiljković S; Milojković M; Bogicević M; Vlahović P
Ann Clin Biochem; 2003 May; 40(Pt 3):232-4. PubMed ID: 12803833
[TBL] [Abstract][Full Text] [Related]
16. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
17. Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients.
Wascher TC; Boes U
Clin Physiol Funct Imaging; 2005 Jan; 25(1):40-6. PubMed ID: 15659079
[TBL] [Abstract][Full Text] [Related]
18. Association of gliclazide and left ventricular mass in type 2 diabetic patients.
Pan NH; Lee TM; Lin MS; Huang CL; Chang NC
Diabetes Res Clin Pract; 2006 Nov; 74(2):121-8. PubMed ID: 16631274
[TBL] [Abstract][Full Text] [Related]
19. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
Johnson JA; Simpson SH; Toth EL; Majumdar SR
Diabet Med; 2005 Apr; 22(4):497-502. PubMed ID: 15787679
[TBL] [Abstract][Full Text] [Related]
20. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
